For patients who received 50 mg once weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI 75 at week 24.
Patsientidel, kes kasutasid kogu uuringu jooksul 50 mg ühe korra nädalas, jätkus ravivastuste paranemine ning 71% neist saavutasid 24. nädalaks PASI 75.